Indication

Rhabdomyosarcoma

Rhabdomyosarcoma is an aggressive malignant soft tissue sarcoma arising from primitive mesenchymal cells committed to skeletal muscle differentiation. Read more about Rhabdomyosarcoma

14 drugs 13 manufacturers

Advertisement

Drugs that treat it

Common Rhabdomyosarcoma therapies.

Showing 1–9 of 14 drugs

DACTINOMYCIN

DACTINOMYCIN·EWING'S SARCOMA·+4
X-GEN PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with Rhabdomyosarcoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Rhabdomyosarcoma.

Rhabdomyosarcoma is an aggressive malignant soft tissue sarcoma arising from primitive mesenchymal cells committed to skeletal muscle differentiation.

It represents the most common soft tissue sarcoma of childhood and adolescence, though it can occasionally develop in adults.

Tumors most frequently arise in the head and neck, genitourinary tract, extremities, and trunk.

Pathophysiologically, the disease is characterized by immature myogenic precursors called rhabdomyoblasts and is classified into distinct histologic and molecular subtypes, predominantly embryonal and alveolar forms, the latter often driven by characteristic PAX3- or PAX7-FOXO1 gene fusions.

Clinically, it typically presents as an enlarging, painless mass or produces site-dependent signs of local tissue invasion and organ dysfunction.

Personalize your experience

Follow Rhabdomyosarcoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it